Bone mineral density was assessed with DEXA (Dual Energy X-Ray Absorptiometry At the end of the study, serum TSH levels decreased from 1.23±0.65 to 0.38±0.51$mu$U/mL (p
📌 3 Key Takeaways
🎯
Objective & Hypothesis:L-thyroxine (L-T4) suppressive therapy for euthyroid nodular goiter is still a treatment of choice.
📊
Key Findings & Data:However, many conceptions have been reported about side effect of this therapy on bone mineral density. in this prospective study, 20 patients (18 premenopausal women and 2 male) with euthyroid nodular goiter; given L-T4 therapy to suppress serum TSH levels between 0.2 and 0.4$mu$U/mL were followed for changes in bone mineral density of lumbar spine (L-1 through L-4), femoral trochanter, intertrochanter, femoral neck and Ward's triangle for 18 months with 6 months interval.
💡
Conclusion & Impact:Bone mineral density was assessed with DEXA (Dual Energy X-Ray Absorptiometry At the end of the study, serum TSH levels decreased from 1.23±0.65 to 0.38±0.51$mu$U/mL (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
L-thyroxine (L-T4) suppressive therapy for euthyroid nodular goiter is still a treatment of choice. However, many conceptions have been reported about side effect of this therapy on bone mineral density. in this prospective study, 20 patients (18 premenopausal women and 2 male) with euthyroid nodular goiter; given L-T4 therapy to suppress serum TSH levels between 0.2 and 0.4$mu$U/mL were followed for changes in bone mineral density of lumbar spine (L-1 through L-4), femoral trochanter, intertrochanter, femoral neck and Ward's triangle for 18 months with 6 months interval. Bone mineral density was assessed with DEXA (Dual Energy X-Ray Absorptiometry At the end of the study, serum TSH levels decreased from 1.23±0.65 to 0.38±0.51$mu$U/mL (p
🔖
Cite This Article
SERT, M., TETİKER, T. (2022). Effects of L-Thyroxine suppressive therapy on bone mineral density. Annals of Medical Sciences, Cilt: 11 - Sayı: 1, 21–24. https://ajindex.com/articles/447434
Papini E, Petrucci L, Guglielmi R, et al: Long-term changes in nodular goiter: a 5-year prospective random-ized trial of levothyroxine suppressive therapy for benign cold thyroid nodules. J Clin Endocrinol Metab, 1998
Ridgway EC: Medical teratment of benign thyroid nod-ules: have we defined a benefit?[Editorial] Ann Intern Med, 1998
Florkowski CM, Brownlie BE, Elliot JR, et al: Bone min-eral density in patients receiving suppressive doses of thyroxine for thyroid carcinoma. N Z Med J, 1993
Muller CG, Bayley TA, Harrison JE, Tsang R: Possiblelimited bone loss with suppressive thyroxine therapy is unlikely to have clinical relevance. Thyroid, 1995
Ross DS, Neer RM, Ridgway EC, Daniels GH: Subclini-cal hyperthyroidism and reduced bone density as a possi-ble result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine. Am J Med, 1987
Diamond T, Nery L, Hales I: A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurments in both premenopausal and post-menopausal women with thyroid carcinoma. J Clin En-docrinol Metab, 1990
Paul TL, Kerrigan J, Kelly AM, et al: Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal women. JAMA,1988
Hayran M, Özdemir O: İkiden Fazla Ortalamanın Karşı-laştırılması. In: Bilgisayar İstatistik ve Tıp. Hekimler Yayın Birliği, MEDİKOMAT, Ankara, 1995
Daniels GH: Thyroid nodules and nodular thyroids: a clinical overview. Compr Ther, 1996
Cooper DS: Clinical review 66: thyroxin suppression therapy for benign nodular disease. J Clin Endocrinol Metab, 1995
Smith SA, Gharib H: Thyroid nodule suppression. Endo-crinol Metab, 1991
Burch HB: Evaluation and management of the solid thy-roid nodule. Endocrinol Metab Clin North Am, 1995
Gharib H, Mazzaferri EL: Thyroxine suppressive therapyin patients with nodular thyroid disease. Ann Intern Med, 1998
De Rosa G, Testa A, Maussier ML, et al: A slightly sup-pressive dose of L-thyroxine does not affect bone turn-over and bone mineral density in pre-and postmenopausal women with nontoxic goiter. Horm Metab Res, 1995
Rosen HN, Moses AC, Garber J, et al: Randomized trial of pamidronate in patients with thyroid cancer: bone den-sity is not reduced by suppressive doses of thyroxine, but is increase